President and CEO of AMAG Pharmaceuticals Inc. (AMAG, Financial) Brian Jg Pereira sells 230,011 shares of AMAG on 11/10/2009 at an average price of $43.76 a share.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions. Amag Pharmaceuticals Inc. has a market cap of $748.8 million; its shares were traded at around $43.74 with and P/S ratio of 386.4.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions. Amag Pharmaceuticals Inc. has a market cap of $748.8 million; its shares were traded at around $43.74 with and P/S ratio of 386.4.
Insiders' Positions with AMAG
- Sell:: President and CEO Brian Jg Pereira sold 5,000 shares of AMAG stock on 08/05/2009 at the average price of 45, the price of the stock has decreased by 2.8% since
Insiders' Positions with AMAG
- Buy:: 10% Owner Capital Partners Gp Llc Adage bought 236,000 shares of AMAG stock on 11/09/2009 at the average price of 44.15, the price of the stock has decreased by 0.93% since
- Buy:: 10% Owner Capital Partners Gp Llc Adage bought 245,088 shares of AMAG stock on 11/05/2009 at the average price of 42.14, the price of the stock has increased by 3.8% since
- Sell:: SVP, Commercial Operations Timothy G Healey sold 399 shares of AMAG stock on 08/03/2009 at the average price of 45.48, the price of the stock has decreased by 3.83% since
